EMFACE Achieves a Remarkable Milestone of 1 Million Treatments in Record Time

EMFACE Celebrates 1 Million Treatments Milestone

In an unprecedented achievement, EMFACE has surpassed the significant milestone of one million treatments worldwide within just two years of its launch. This remarkable speed establishes EMFACE as the fastest-growing non-invasive facial lifting procedure, revolutionizing the aesthetics landscape.

Transforming the Aesthetics Industry

Developed by BTL, a prominent global leader in medical technology, EMFACE entered the market in 2022 as the first operator-independent procedure to effectively target facial muscles while enhancing skin quality concurrently. This innovative treatment offers a non-invasive solution to achieve a youthful and lifted appearance without the need for needles or extensive downtimes. Dr. Yael Halaas, a New York City-based facial plastic surgeon, remarked on its capability to stimulate elevator muscles, stating, "This approach enables us to elevate facial features from within—a significant advancement compared to traditional injectables and energy-based devices."

Rapid Global Adoption

Since its launch, EMFACE has captured the interest of both medical professionals and patients worldwide, touting the absence of needles and discomfort. The treatment’s appeal continues to grow, further solidified by the introduction of specialized submental and under-eye applicators that enhance its versatility. Medical practitioners greatly praised the eye applicators when they were unveiled at the International Master Course on Aging Science (IMCAS) World Conference in Paris in January 2025. Dr. Kyungkook Hong, a board-certified dermatologist from Seoul, Korea, emphasized the multifunctionality of EMFACE, declaring it a transformational procedure suitable for individualized facial rejuvenation.

Integration and Expansion in Aesthetic Practices

As more professionals integrate EMFACE into their treatment protocols, it is becoming an integral part of comprehensive facial rejuvenation strategies, effectively complementing traditional injectables. With steady growth and recognition, EMFACE not only enhances aesthetic procedures but also demonstrates the potential for non-invasive treatment options in the beauty industry.

The excitement surrounding the treatment’s rapid adoption has led Tomas Schwarz, CEO of BTL, to affirm, "Reaching one million treatments within two years showcases the exciting technology and value EMFACE brings to the medical community and its patients. We are dedicated to advancing non-invasive solutions further in the coming years."

Looking Ahead

As EMFACE continues to forge ahead with its innovative treatments, the landscape of facial rejuvenation is poised for significant change. Clinicians and patients alike are recognizing the benefits of non-invasive options, setting a new standard in the quest for youthful vitality without the drawbacks typically associated with cosmetic procedures. For more insights into EMFACE and its pioneering technology, please visit www.emface.com.

About BTL

Founded in 1993, BTL has positioned itself as one of the leading manufacturers of medical equipment in the world. With a robust team of over 3,000 employees across more than 80 countries, BTL specializes in non-invasive solutions for body shaping, skin tightening, and various medical aesthetic treatments, including intimate health and mental wellness. Notable BTL products include EMSCULPT NEO®, EMFACE®, and EXION™, among others, continuously pushing the envelope in terms of innovation within the medical aesthetic domain. For more information about BTL and its offerings, visit www.btlaesthetics.com.